1. Scrip
  2. >>Business
  3. >>Deals

SK Bioscience Snaps Up IDT Biologika To Accelerate Growth

'Perfect Fit', New Capabilities

 
• By Jung Won Shin

SK Bioscience’s acquisition of top 10 CDMO marks first major acquisition as part of its growth acceleration strategy and the biggest such investment so far by a Korean vaccines firm. Execs say deal is aligned with SK Group’s wider moves to 'rebalance' its businesses.

Jae-Yong Ahn, CEO of SK Bioscience
IDT Acquisition To Bring New Capabilities, SK Bioscience CEO Jae-Yong Ahn says • Source: SK Bioscience

South Korean vaccines and biotech company SK Bioscience will acquire a 60% stake in the major Germany contract development and manufacturing organization (CDMO) IDT Biologika in a deal worth KRW339bn ($244m), in a bid to accelerate growth, diversify into new businesses and enter global markets.

The deal, expected to close in the next few months, values IDT Biologika at about KRW656bn and marks the first major acquisition for SK Bioscience since it announced a growth acceleration plan in 2022, as

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

 
• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Trump’s MFN Executive Order More Rhetoric Than Action

 
• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.